Patient-Oriented Evidence That Matters
No Effect on Mortality with Oxygen Therapy in Nonhypoxemic Patients with Suspected MI
Am Fam Physician. 2018 Feb 15;97(4):online.
Does use of oxygen therapy improve outcomes in patients with suspected myocardial infarction (MI) who do not have hypoxemia at baseline?
In patients with suspected MI and normal oxygen levels, giving immediate supplemental oxygen therapy does not improve mortality at one year. Although this study was underpowered because of fewer than expected deaths in the control group, the results were consistent across all subgroups, as well as with findings from other literature. (Level of Evidence = 1b)
These investigators randomized patients with suspected MI (chest pain or shortness of breath with electrocardiographic changes of ischemia or elevated troponin levels) and an oxygen saturation of 90% or higher on pulse oximetry to receive oxygen therapy (n = 3,311) or ambient air (n = 3,318). Patients were recruited from ambulance services, emergency departments, coronary care units, and catheterization laboratories. The final diagnosis was MI in 76% of the included patients. The remaining 24% of patients were more likely to have unspecified chest pain, other cardiac disease, or angina. In the oxygen group, oxygen was delivered at 6 L per minute for six to 12 hours via an open face mask. The median duration of oxygen therapy was 11.64 hours. Overall, 1.9% of patients in the oxygen group and 7.7% of patients in the ambient air group received oxygen therapy outside of the protocol because of development of hypoxemia, but were included in the intention-to-treat analysis. Furthermore, 9% of patients in the oxygen group and 3% of patients in the ambient air group did not complete participation through the end of the treatment period, and were excluded from the per-protocol analysis.
For the primary outcome of all-cause death at one year, there was no significant difference detected between the two groups (mortality rate = 5% in the oxygen group vs. 5.1% in the ambient air group; P = .80). Results were similar in the per-protocol analysis and across prespecified subgroups. Additionally, no differences were detected in death at 30 days or in rates of rehospitalization for MI at 30 days or one year. Of note, the power calculation for the primary outcome was based on an estimated death rate in the control group of 14%. Because the observed rate was much lower at 5.1% (possibly because 24% of the patients did not actually have MI as a final diagnosis), this study did not have adequate power to detect a small difference in the oxygen group if such a difference existed.
Study design: Randomized controlled trial (nonblinded)
Funding source: Government
Setting: Inpatient (any location)
Reference: Hofmann R, James SK, Jernberg T, et al.; DETO2X–SWEDEHEART Investigators. Oxygen therapy in suspected acute myocardial infarction. N Engl J Med. 2017;377(13):1240–1249.
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 1, 2020
Access the latest issue of American Family Physician